<code id='86E1E2B8D8'></code><style id='86E1E2B8D8'></style>
      • <acronym id='86E1E2B8D8'></acronym>
      <center id='86E1E2B8D8'><center id='86E1E2B8D8'><tfoot id='86E1E2B8D8'></tfoot></center><abbr id='86E1E2B8D8'><dir id='86E1E2B8D8'><tfoot id='86E1E2B8D8'></tfoot><noframes id='86E1E2B8D8'>
      • <optgroup id='86E1E2B8D8'><strike id='86E1E2B8D8'><sup id='86E1E2B8D8'></sup></strike><code id='86E1E2B8D8'></code></optgroup>
        5. <b id='86E1E2B8D8'><label id='86E1E2B8D8'><select id='86E1E2B8D8'><dt id='86E1E2B8D8'><span id='86E1E2B8D8'></span></dt></select></label></b><u id='86E1E2B8D8'></u>
          <i id='86E1E2B8D8'><strike id='86E1E2B8D8'><tt id='86E1E2B8D8'><pre id='86E1E2B8D8'></pre></tt></strike></i>
          
    
          
      
          
       
      
          
        
      
          
      
          
        
          
          
          
            
          
            
          
              
          
                
          focus 
          
                
          
                
          
              
          
            
          
            
            
          
          
          
       
        
          
      
          
      
          
        
          
        
          
          
            
          
                           
          focus  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：71648
                                  
                                    
          
                                    
          Novo Nordisk headquarters -- health coverage from STAT
          LISELOTTE SABROE/Scanpix/AFP via Getty Images
          LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines. 
          Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure. 
          advertisement
          The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Obesity experts on risks of Wegovy, Ozempic weight loss drugs
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          
            
          
           
            
          
          
          
       
          
        
          
        
      
          
      
          
                                                
        
          Wikipedia
          
                  
          

                    
          
            
          
              
                Dobbs anniversary: the lost opportunity of abortion as health care
                
          
                        
              
          
                Dobbs anniversary: the lost opportunity of abortion as health care
                
          
                  
          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                Readout LOUD podcast: ESMO highlights & Roivant's big deal
                
          
                        
              
          
                Readout LOUD podcast: ESMO highlights & Roivant's big deal
                
          
                  
          Howdocancerdrugswork?Whatmakesbiotechstocksgoup?Andwhyareventurecapitalistssooptimistic?Wecoverallth
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
                   
          
            
          
              
                In age of alternative facts, a scholarly course on calling out crap
                
          
                        
              
          
                In age of alternative facts, a scholarly course on calling out crap
                
          
                  
          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor
          
                
          
                
                  read more
                    
                  
              
          
            
          
          
          
         
        
          
          
        
          

          
          
            
          
          
          
            
          Obesity experts on risks of Wegovy, Ozempic weight loss drugs
          
            
          ObesityexpertsJamyArd(left)andRobertLustigspeakatapanelduringthe2023STATBreakthroughSummit.SarahGonz
          
          
          
          
          
            read more